William Hoffman - May 16, 2024 Form 4 Insider Report for Inari Medical, Inc. (NARI)

Role
Director
Signature
/s/ Shannon Trevino, attorney-in-fact for William Hoffman
Stock symbol
NARI
Transactions as of
May 16, 2024
Transactions value $
-$1,863,977
Form type
4
Date filed
5/17/2024, 06:07 PM
Previous filing
May 3, 2024
Next filing
May 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NARI Common Stock Sale -$1.52M -32.7K -3.39% $46.51 933K May 16, 2024 Direct F1, F2
transaction NARI Common Stock Sale -$343K -7.3K -0.78% $47.00 925K May 16, 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $45.87 to $46.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $46.87 to $47.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.